The Swiss biotechnology company BioVersys has marked a milestone in its history by initiating its listing on the prestigious Swiss stock exchange, SIX Swiss Exchange. The company's stock market debut began at 36.50 Swiss francs per share, giving it a market capitalization of around 216 million Swiss francs. This strategic move not only symbolizes a momentous step forward for BioVersys, but also for the biotechnology sector in Switzerland, further consolidating its position as a global hub of innovation.
BioVersys' Initial Public Offering (IPO) has been met with notable enthusiasm in the market. With a share capital consisting of 3,692,285 registered shares, the company expanded its financial horizon through the issuance of 2,222,221 new shares during the IPO, each valued at 36 Swiss francs. This successful sale has enabled the company to raise a placement volume close to 80 million Swiss francs, adding the over-allocation option of 138,888 shares.
Marc Gitzinger, CEO of BioVersys, did not hide his enthusiasm in the face of this monumental achievement. "The strong demand and investors' interest are a great motivation. This backing will allow us to rapidly advance our clinical trials and expand our portfolio of new medicines, maintaining our commitment to provide urgent antibiotic solutions to seriously ill patients worldwide," said Gitzinger. The capital raised in the IPO will be primarily allocated to advancing its flagship antibiotic, BV100, which aims to combat infections acquired in hospital settings and is moving toward Phase III clinical trials.
BioVersys' stock market debut was also celebrated by Bjørn Sibbern, CEO of SIX, who highlighted the attraction Switzerland exerts on biotechnology companies. "This event demonstrates that our country offers an attractive environment for growth and success in the life sciences. We are proud to support BioVersys in this new chapter," said Sibbern. The inclusion of BioVersys in the Swiss Performance Index (SPI) confirms its consolidation in the market and reinforces Switzerland's role as a leader in the field of life sciences in Europe.
Since its beginnings as a modest startup in Basel, BioVersys has come a long way, navigating a path full of challenges to position itself as an influential company in the global market. The growth strategy adopted by the company, together with the support of its investors, promises to continue renewing BioVersys' commitment to the development of innovative and effective antibacterial solutions. This debut on the Swiss stock exchange is not only a reflection of the success of its business vision, but also a substantial contribution to Switzerland's recognition as a hub of biotechnology and scientific innovation.
